3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Primary Myelofibrosis
24
Leukemia, Myeloid, Acute
16
Myeloproliferative Disorders
15
Polycythemia Vera
12
Leukemia
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Myelodysplastic Syndromes
9
Thrombocythemia, Essential
8
Graft vs Host Disease
8
Recurrence
6
Neoplasms
6
Myelodysplastic-Myeloproliferative Diseases
4
Lymphoma, T-Cell
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Lymphoma, T-Cell, Cutaneous
3
Leukemia, Prolymphocytic, T-Cell
3
Leukemia, Myelomonocytic, Chronic
3
Hematologic Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Bronchiolitis Obliterans Syndrome
3
Triple Negative Breast Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Interventions
Specimen Handling
8
Tamoxifen
6
Standard of Care
4
Practice Guidelines as Topic
4
Radiotherapy
3
Methods
3
Sentinel Lymph Node Biopsy
2
Radiation Dose Hypofractionation
2
Radiation
2
Educational Status
2
Early Intervention, Educational
2
Counseling
2
ruxolitinib
1
pembrolizumab
1
exemestane
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
auricularum
1
abemaciclib
1
Watchful Waiting
1
Telemedicine
1
Taxes
1
Tablets
1
Surveys and Questionnaires
1
Starch
1
Reverse Transcriptase Polymerase Chain Reaction
1
Ranitidine
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Carcinoma In Situ
×
ruxolitinib
×
1 year
×
Clear all
NCT02928978
2026-04-13
TBCRC042
Baylor Breast Care Center
Phase 2
Completed
84 enrolled